KRAS G12P

CI-VAR-00001614Explore in graph →CIViC 5342

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Solid Tumors, Advanced1unmapped disease
KRAS G12C OR KRAS G12D OR KRAS G13D OR RET M918T OR KRAS G12A OR KRAS G12V OR KRAS G12R OR KRAS Amplification OR KRAS G12S OR KRAS G13R OR KRAS G12P	Sorafenib	Predictive	B	Supports Sensitivity Response	3	submitted	EID12700 In the randomized discontinuation Phase II MOST-Plus trial of advanced/metastatic solid tumors with sorafenib-targeted somatic alterations (NCT02029001; n = 35 randomized; KRAS G12A/C/D/P/R/S/V n = 29… (full text at CIViC) PMID 37444551 · Trédan et al., 2023 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.